Veradermics Inc(MANE) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 16 at 4:33 AM ET (Korea 9/16 17:33)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | - | Insider Own | 27.61% | Shs Outstand | 41.8M | Perf Week | 0.06% |
| Market Cap | 4.34B | Forward P/E | - | EPS next Y | 7.89% | Insider Trans | -7.69% | Shs Float | 30.3M | Perf Month | -7.83% |
| Enterprise Value | 3.52B | PEG | - | EPS next Q | -0.61 | Inst Own | 69.94% | Short Float | 13.31% | Perf Quarter | 7.92% |
| Income | - | P/S | - | EPS this Y | 15.85% | Inst Trans | 22.84% | Short Ratio | 5.48 | Perf Half Y | 82.42% |
| Sales | - | P/B | 5.33 | EPS next 5Y | 21.43% | ROA | - | Short Interest | 4.03M | Perf YTD | 205.56% |
| Book/sh | 19.49 | P/C | 5.29 | EPS past 3/5Y | -117.94% - | ROE | - | 52W High | -20.84% ($131.24) | Perf Year | - |
| Cash/sh | 19.62 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 224.66% ($32.00) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | 5.05% 5.42% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 5.64 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 70.53 | EPS Q/Q | -44.05% | Profit Margin | - | RSI (14) | 51.43 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 70.53 | Sales Q/Q | - | SMA20 | 2.31% ($101.54) | Beta | - | Target Price | $163.5 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/11 | SMA50 | -3.21% ($107.34) | Rel Volume | 1.28 | Prev Close | $101.7 |
| Employees | 21 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 11.4% - | SMA200 | 18.32% ($87.8) | Avg Volume(3M) | 0.73M | Price | $103.89 |
| IPO | 2026/2/4 | Option/Short | Yes/Yes | Trades | 8658 | Volume | 939,018 | Change | 2.15% |
Company
MANE is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
A clinical-stage biopharmaceutical company developing treatments for dermatological conditions. Its lead candidate is an oral, extended-release minoxidil targeting male and female pattern hair loss, which has shown positive Phase 3 clinical results and is being advanced toward commercialization. The company specializes in dermatological therapeutics, including hair loss treatments.
Over the past 1 year, roughly in the middle
21% below its 1-year high.
MANE makes money exceptionally well
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +15.8% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Long-term returns are close to the market
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 69.9%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
LFSC 0.03%
XPH 0.02%
TOS 0.02%
IHE 0.01%
FPX 0.00%It ranks #4 in the industry
Based on market cap of $4B.
MANE $4B PER -
VRTX $130B PER 29.9
REGN $80B PER 19.1
ARGX $61B PER 37.3
FAQ
What kind of company is MANE?
MANE belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of MANE?
The market cap of MANE is approximately $4.3B, ranking 1,487 within its sector.
What is the 52-week high and low for MANE?
MANE has recorded a 52-week high of $131.24 and a low of $32.00.
